Co-Diagnostics Inc.

5.40-0.0900-1.64%Vol 212.51K1Y Perf -36.90%
Jun 24th, 2022 16:00 DELAYED
BID5.30 ASK5.46
Open5.55 Previous Close5.49
Pre-Market- After-Market5.50
 - -  0.10 1.85%
Target Price
20.50 
Analyst Rating
Strong Buy 1.00
Potential %
279.63 
Finscreener Ranking
★★★★★     77.65
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★★★★     74.83
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
★★★★★     92.36
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
21.32 
Earnings Rating
Strong Buy
Market Cap183.53M 
Earnings Date
11th Aug 2022
Alpha0.10 Standard Deviation0.58
Beta-1.15 

Today's Price Range

5.365.61

52W Range

3.6611.82

5 Year PE Ratio Range

-13.5014.40

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
4.85%
1 Month
16.63%
3 Months
-6.25%
6 Months
-42.61%
1 Year
-36.90%
3 Years
620.00%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CODX5.40-0.0900-1.64
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
9.20
9.60
0.00
0.00
808.77K
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
88.50
45.30
45.80
-21 863.40
40.34
RevenueValueIndustryS&P 500US Markets
100.56M
2.96
1.26K
-
Earnings HistoryEstimateReportedSurprise %
Q01 20220.180.2644.44
Q04 20210.150.2566.67
Q03 20210.210.3880.95
Q02 20210.230.3343.48
Q01 20210.200.2630.00
Q04 20200.490.43-12.24
Q03 20200.540.53-1.85
Q02 20200.610.43-29.51
Earnings Per EndEstimateRevision %Trend
6/2022 QR0.1536.36Positive
9/2022 QR0.1344.44Positive
12/2022 FY0.6759.52Positive
12/2023 FY0.71--
Next Report Date11th Aug 2022
Estimated EPS Next Report0.15
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume212.51K
Shares Outstanding33.99K
Shares Float33.88M
Trades Count2.50K
Dollar Volume1.16M
Avg. Volume400.06K
Avg. Weekly Volume354.93K
Avg. Monthly Volume490.72K
Avg. Quarterly Volume354.54K

Co-Diagnostics Inc. (NASDAQ: CODX) stock closed at 5.4 per share at the end of the most recent trading day (a -1.64% change compared to the prior day closing price) with a volume of 212.51K shares and market capitalization of 183.53M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 39 people. Co-Diagnostics Inc. CEO is Dwight H Egan.

The one-year performance of Co-Diagnostics Inc. stock is -36.9%, while year-to-date (YTD) performance is -39.53%. CODX stock has a five-year performance of %. Its 52-week range is between 3.66 and 11.82, which gives CODX stock a 52-week price range ratio of 21.32%

Co-Diagnostics Inc. currently has a PE ratio of 4.00, a price-to-book (PB) ratio of 1.18, a price-to-sale (PS) ratio of 1.74, a price to cashflow ratio of 4.40, a PEG ratio of 2.32, a ROA of 32.67%, a ROC of 35.93% and a ROE of 36.84%. The company’s profit margin is 40.34%, its EBITDA margin is 45.80%, and its revenue ttm is $100.56 Million , which makes it $2.96 revenue per share.

Of the last four earnings reports from Co-Diagnostics Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.15 for the next earnings report. Co-Diagnostics Inc.’s next earnings report date is 11th Aug 2022.

The consensus rating of Wall Street analysts for Co-Diagnostics Inc. is Strong Buy (1), with a target price of $20.5, which is +279.63% compared to the current price. The earnings rating for Co-Diagnostics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Co-Diagnostics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Co-Diagnostics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 18.03, ATR14 : 0.34, CCI20 : 91.09, Chaikin Money Flow : 0.05, MACD : 0.10, Money Flow Index : 52.84, ROC : -5.43, RSI : 55.48, STOCH (14,3) : 60.98, STOCH RSI : 0.70, UO : 44.90, Williams %R : -39.02), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Co-Diagnostics Inc. in the last 12-months were: Eugene Durenard (Sold 2 000 shares of value $20 910 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
1 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Moderate Buy
1.67

Co-Diagnostics Inc.

Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV. The company's diagnostics systems enable very rapid, low-cost, sophisticated molecular testing for organisms and genetic diseases by greatly automating historically complex procedures in both the development and administration of tests.

CEO: Dwight H Egan

Telephone: +1 801 438-1036

Address: 2401 South Foothill Drive, Salt Lake City 84109, UT, US

Number of employees: 39

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

56%44%

News

Stocktwits